Synopsis Insulin-like growth factor-1 (IGF-1) is an important fetal growth regulator. The level of IGF-1 increases with gestational age, particularly during the second and third trimesters of pregnancy. However, in the case of preterm births, the level decreases rapidly and remains low for the first few weeks of life. Studies have reported that lower serum IGF-1 levels at birth results in increased risk of complications of prematurity. This week’s “ MED FACT ” discusses a phase 2, multicenter, randomized control trial from The Journal of Pediatrics, “ rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial ”, 2019. Authors: D.
Ley, B. Hallberg, I. Hansen-Pupp, et. al. Key Takeaways The use of rhIGF-1/rhIGFBP-3 (also known as Mecasermin Rinfabate ) in preterm infants significantly decreases the occurrence of severe bronchopulmonary dysplasia (BPD) with a…
